RxDoctor Payments Data

Steven Eisenberg, MD

Cardiovascular Disease · Atlanta, GANPI 1902849565

Payments from drug & device makers

$24,395in general payments, 2019–2025

Across 490 payments — averaging $49.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$6K
  • Amgen$5K
  • Boston Scientific$3K
  • Edwards Lifesciences$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Johnson & Johnson$1K
  • plus $5K from 27 others

What the payments were for

  • Consulting fees$5202%
  • Speaking & faculty fees$12,48551%
  • Travel & lodging$1,2965%
  • Food & beverage$9,89641%
  • Education$1981%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,395 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$346,396
Medicare patients
1,172
Services billed
4,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban755$922,550
Repatha SureclickEvolocumab260$342,977
XareltoRivaroxaban201$242,980
Praluent PenAlirocumab76$85,648
JardianceEmpagliflozin43$70,234
EntrestoSacubitril/Valsartan22$32,703
MultaqDronedarone Hcl13$20,471
Ezetimibe567$16,352
Dabigatran EtexilateDabigatran Etexilate Mesylate32$11,600
FarxigaDapagliflozin Propanediol12$10,453
Rosuvastatin Calcium674$7,648
Dofetilide21$6,683
Atorvastatin Calcium643$5,303
ClopidogrelClopidogrel Bisulfate415$4,748
Metoprolol Succinate323$4,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$588$922,550755 claims
Johnson & JohnsonXarelto$1,203$242,980201 claims
Boehringer IngelheimJardiance$5,834$70,23443 claims
NovartisEntresto$950$32,70322 claims
Sanofi-aventis U.S. LLCMultaq$160$20,47113 claims
AstraZenecaFarxiga$624$10,45312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →